Posts

Posted on

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

— ~$3.7 Million Clinical Grant to Fund U.S. Phase 1 Study of RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis —

NEW YORK–(BUSINESS WIRE)–
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $3.7 million CLIN2 grant award to support the clinical development of its lentiviral vector (LVV)-based gene therapy, RP-L401, for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder characterized by skeletal deformities, neurologic abnormalities and bone marrow failure. The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allowed $3 billion in state funding for stem cell research conducted in California. This will be Rocket’s second CIRM grant after receiving one in 2019 for the development of the company’s gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I).

“We’re grateful the CIRM has recognized the promise of RP-L401 for IMO, a devastating pediatric rare disease for which the primary treatment option is allogeneic bone marrow transplant,” said Jonathan Schwartz, M.D. Chief Medical Officer and Senior Vice President of Rocket. “RP-L401 could be a potentially curative treatment for this devastating disorder that affects children at a young age, and we are thankful to have this meaningful support from the CIRM to move our program forward for these families.”

Rocket’s Investigational New Drug Application (IND) for RP-L401 was accepted by the U.S. Food and Drug Administration (FDA) in June of 2020, and the gene therapy received Fast Track designation from the FDA in August 2020. Proceeds from the grant will help fund clinical trial costs, as well as provide manufactured drug product for Phase 1 patients enrolled at the U.S. clinical trial site, University of California, Los Angeles, led by principal investigator Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles. The non-randomized, open-label Phase 1 clinical trial will enroll two pediatric patients, one month of age or older. The trial is designed to assess safety and tolerability of RP-L401, as well as preliminary efficacy, including potential improvements in bone abnormalities/density, hematologic status and endocrine abnormalities. Further information about the clinical program is available here.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

RP-L401 was in-licensed from Lund University and Medizinische Hochschule Hannover. Rocket’s IMO research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-12095). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other agency of the State of California.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed November 6, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Claudine Prowse, Ph.D.

SVP, Strategy & Corporate Development

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Health Stem Cells Genetics Clinical Trials Pharmaceutical Cardiology Biotechnology

MEDIA:

Posted on

Warrior Gold Announces Advisory Board Appointment and Provides Exploration and Corporate Update

Warrior Gold Announces Advisory Board Appointment and Provides Exploration and Corporate Update

TORONTO–(BUSINESS WIRE)–Warrior Gold Inc. (TSX-V – WAR) (“Warrior Gold” or the “Company”) ispleased to provide a corporate update including the immediate appointment of Linda Wrong, P.Geo., CSR-P, to the Company’s Advisory Board. Ms. Wrong is a Professional Geoscientist and Certified Sustainability Practitioner with over 25 years of international experience in the exploration and mining industry, beginning her career as an exploration geologist in the Kirkland Lake Area with Kerr Addison Mines. As former Vice President of Environment and Permitting at Labrador Iron Mines, Linda successfully led the team through the environmental assessment and permitting processes for the James Mine, obtaining the required permits which led to the start of operations within two years of submitting regulatory filings. Following Labrador Iron Mines, Linda assumed senior environmental and sustainability leadership positions at Barrick Gold, Hudbay Minerals, and Lundin Mining. Linda is currently the Global General Manager, Corporate Environment at Glencore International, leading environmental initiatives across their international operations.

Danièle Spethmann, President and CEO of Warrior Gold stated, “We are very pleased that Linda has joined the Warrior Gold team. Linda’s extensive geological and industry expertise across northern Canada, including the Kirkland Lake camp, as well as her familiarity with the provincial and federal Canadian environmental and permitting processes, will support the Company’s efforts to advance the Goodfish- Kirana project.”

Exploration Update

The Company is also pleased to provide an exploration update further to its press release of August 20th announcing the initiation of a field mapping program and a collaborative advanced study program led by Dr. Neil Banerjee of Western University’s Department of Earth Sciences and Dr. Lisa Van Loon of LISA CAN Analytical Solutions. To date, 13 drill core samples and 84 pulps have been selected from the Goodfish-Kirana “A” and “C” Zones for a synchrotron mineral cluster analysis. The program will assess the link between alteration and mineralization from these zones, as well as the newly recognized mineralization (“A” Zone NS-FW) identified in the summer drill program. These samples will also be submitted for petrography, X-ray microscopy, and microprobe analysis to provide mineralogy of ore phases and gold textural information.

The Company is currently assessing all recently acquired drill data and additional analytical results (multi-element and screen-metallic) in conjunction with reprocessing historical raw geophysical data in advance of a drill-targeting exercise. In addition, the Company will be initiating an in-situ borehole survey test program consisting of (a) an Optical Televiewer (OTV) which collects a detailed high-resolution oriented image of the borehole wall that provides structural information such as the orientation of veins, lithological contacts, shear fabrics, etc., and (b) a Mineralization Logging Suite (MLS) survey comprised of Induced Polarization (IP), Resistivity and Natural Gamma. This work is expected to be completed by the end of November and will be used to validate previously collected structural data, capture structural information in domains where oriented drilling failed and provide a geophysical signature of mineralization which will aid in future geophysical program planning.

Infrastructure work includes renovating the Company’s new core logging facilities in the town of Kirkland Lake.

Corporate Update

On October 22, 2020, the Company held its Annual General and Special meeting of shareholders (the “Meeting”) which was shared online via Zoom. A total of 26,464,815 common shares of the Company were represented, approximately 33% of the total number of shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including the election of four management nominees to the board of directors, the appointment of Crowe MacKay LLP as auditors for the ensuing year, the authorizing of the directors to fix their remuneration, and the re-approval of the Company’s 10% stock option plan.

The Company also confirms the extension to the expiry date of 5,322,739 warrants. Further to the Company’s press release of September 23, 2020, the TSX Venture Exchange provided approval for the extension of time for exercise. The approved extension provides for 4,533,239 warrants that were originally scheduled to expire on September 25, 2020, to expire on March 25, 2020, and for 789,500 warrants originally scheduled to expire on November 20, 2020, to expire on May 20, 2021. The Company did not amend the exercise price of $0.15.

Warrior Gold also announces that the Company will be participating at the 121 Mining Investment EMEA virtual investment conference being held November 18th through November 20th. This event connects exploration and mining management teams with investors from institutional funds, private equity groups, family offices, and sector analysts via one-on-one, 30-minute video meetings. Danièle Spethmann, CEO and Melissa Render, Principal Consulting Geologist, will be participating in these meetings. The Company highlights that these sessions will be held live.

About Warrior Gold Inc.

Warrior Gold is a TSX Venture Exchange-listed Company that owns the Goodfish-Kirana Property located five km from the town of Kirkland Lake, Ontario. The Property is located in the historic Kirkland Lake Gold Camp which is situated in the prolific Abitibi Greenstone Belt, recognized as one of the world’s highest grade greenstone belts with over 200 million ounces of gold produced to date.

The Goodfish-Kirana Property is 11.5 km long by roughly three km wide (34 km2) and contains three major structural trends: the east-west trending Kirana Deformation Zone; the northeast-trending Goodfish Deformation Zone; and the Victoria Creek Deformation Zone on the recently acquired Sutton claims on the northeast side of the property. The Property contains numerous historical gold showings, as well as 18 historical pits and shafts.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. The forward-looking statements are based on certain key expectations and assumptions made by the Company. Although Warrior Gold believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Warrior Gold can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in the Company’s Management Discussion and Analysis of the financial condition and results of operations for the year ended March 31, 2020 and the first quarter ended June 30, 2020, which are available at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Warrior Gold undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Danièle Spethmann, P.Geo.

President & CEO

Warrior Gold Inc.

+1 647 344-3433

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Forest Products Natural Resources Mining/Minerals

MEDIA:

Posted on

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results

TORONTO–(BUSINESS WIRE)–
Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the filing of its financial and operating results for the fiscal quarter ended September 30, 2020. The Company’s unaudited fiscal Q2 2021 condensed interim consolidated financial statements and MD&A are available on SEDAR.

“We’ve made tremendous progress this quarter in preparing our lead drug for Phase III trials and partnering,” commented Dan Legault, Antibe’s CEO. “We are getting closer to the start of our Phase III program, with a total of eight Phase III-enabling studies now running in parallel. Additionally, the recent commercial data strengthens our position as we engage partners for the large markets. Finally, we are executing our capital markets strategy to increase institutional awareness and liquidity, highlighted by the recent graduation to the TSX. We look forward to providing a comprehensive corporate update in the coming weeks.”

Q2 2021 Highlights

  • Announced robust secondary data from otenaproxesul’s Phase IIB dose-ranging, efficacy study, confirming the drug’s remarkable potency shown in earlier top-line results;
  • Completed third party studies for the seven largest markets, framing an impressive commercial opportunity for otenaproxesul;
  • Initiated two animal toxicology studies required for all companies by the US Food and Drug Administration to begin Phase III trials (six additional such studies have commenced in the current quarter);
  • Launched pipeline expansion initiatives aimed at developing new intellectual property based on the Company’s hydrogen sulfide platform;
  • Commenced a proprietary naming initiative for otenaproxesul with a leading global branding agency to determine the commercial brand/trademark;
  • Engaged Stern IR, a premier investor relations agency for healthcare and biotechnology companies worldwide, to support Antibe’s institutional outreach in the US; and
  • Completed the quarter with a cash balance of $22.5 million.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (“NSAIDs”) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with NSAIDs. Antibe’s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. Learn more at antibethera.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-922-3460

[email protected]

Stern Investor Relations

Courtney Turiano

+1 212-362-1200

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo
Posted on

CI Global Asset Management Announces November 2020 Distributions for CI ETFs

CI Global Asset Management Announces November 2020 Distributions for CI ETFs

NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

TORONTO–(BUSINESS WIRE)–
CI Global Asset Management (CI GAM) announces the following regular cash distributions for the month ending November 30, 2020 in respect of CI ETFs. In all cases, the distribution will be paid on or before November 30, 2020 to unitholders of record on November 24, 2020. The ex-dividend date for all ETFs is November 23, 2020, with the exception of CI First Asset High Interest Savings ETF, which has an ex-dividend date of November 24, 2020.

 

Trading Symbol

Distribution Amount

(per unit)

CI First Asset Canadian Convertible Bond ETF

CXF

$0.0400

CI First Asset Active Utility & Infrastructure ETF

FAI

$0.0422

CI First Asset Active Credit ETF

FAO

$0.0450

FAO.U

$0.0450 (US$)

CI First Asset Active Canadian Dividend ETF

FDV

$0.0312

CI First Asset Short Term Government Bond Index Class ETF

FGB

$0.0287

CI First Asset Investment Grade Bond ETF

FIG

$0.0320

FIG.U

$0.0248 (US$)

CI First Asset Long Duration Fixed Income ETF

FLB

$0.0349

CI First Asset Preferred Share ETF

FPR

$0.0768

CI First Asset Enhanced Short Duration Bond Fund (ETF Series)

FSB

$0.0235

FSB.U

$0.0235 (US$)

CI First Asset Canadian REIT ETF

RIT

$0.0675

CI Global Asset Allocation Private Pool (ETF Series)

CGAA

$0.0164

CI First Asset High Interest Savings ETF

CSAV

$0.0233

CI Lawrence Park Alternative Investment Grade Credit ETF

CRED

$0.0500

CRED.U

$0.0500 (US$)

CI Marret Alternative Absolute Return Bond ETF

CMAR

$0.0500

CMAR.U

$0.0500 (US$)

CI Global REIT Private Pool (ETF Series)

CGRE

$0.0860

CI Global Infrastructure Private Pool (ETF Series)

CINF

$0.0690

CI Global Real Asset Private Pool (ETF Series)

CGRA

$0.0770

CI DoubleLine Core Plus Fixed Income US$ Fund (ETF Series)

CCOR

$0.0371

CCOR.B

$0.0349

CCOR.U

$0.0371 (US$)

CI DoubleLine Income US$ Fund (ETF Series)

CINC

$0.0690

CINC.B

$0.0659

CINC.U

$0.0690 (US$)

CI DoubleLine Total Return Bond US$ Fund (ETF Series)

CDLB

$0.0301

CDLB.B

$0.0283

CDLB.U

$0.0301 (US$)

Supporting investors’ needs

Stay in the market, minimize costs, and take advantage of a smart, simple and efficient feature designed to support investors’ needs. The CI Distribution Reinvestment Plan (DRIP) will automatically reinvest cash distributions into the CI ETF making the distribution. All of the distributions indicated in the table above will be paid in cash unless the unitholder has enrolled in the applicable DRIP of the respective ETF. A copy of the Distribution Reinvestment Plan is available at www.firstasset.com.

About CI Global Asset Management

CI Global Asset Management is one of Canada’s largest investment management companies. It offers a wide range of investment products and services and is on the web at www.ci.com. CI Global Asset Management is a subsidiary of CI Financial Corp. (TSX: CIX), an independent company offering global asset management and wealth management advisory services with $202.4 billion in total assets as of October 31, 2020.

This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase exchange-traded funds (ETFs) managed by CI Global Asset Managementand is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard.

Commissions, management fees and expenses all may be associated with an investment in ETFs. You will usually pay brokerage fees to your dealer if you purchase or sell units of an ETF on recognized Canadian exchanges. If the units are purchased or sold on these Canadian exchanges, investors may pay more than the current net asset value when buying units of the ETF and may receive less than the current net asset value when selling them. Please read the prospectus before investing. Important information about an exchange-traded fund (ETF) is contained in its prospectus. ETFs are not guaranteed; their values change frequently and past performance may not be repeated.

CI Global Asset Management is a registered business name of CI Investments Inc.

©CI Investments Inc. 2020. All rights reserved.

For further information:

CI Global Asset Management

416-642-1289

1‐877‐642‐1289

www.firstasset.com

Murray Oxby

Vice-President, Corporate Communications

CI Global Asset Management

416-681-3254

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Bruker Announces Quarterly Dividend

Bruker Announces Quarterly Dividend

BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock. The dividend will be paid on December 18, 2020 to stockholders of record as of December 1, 2020.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Miroslava Minkova

Director, Investor Relations & Corporate Development

Bruker Corporation

T: +1 (978) 663 – 3660, ext. 1479

E: [email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Devices Health Other Science Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo
Posted on

Bitfarms Announces 2020 Third Quarter Results Release Date

Bitfarms Announces 2020 Third Quarter Results Release Date

TORONTO & BROSSARD, Québec–(BUSINESS WIRE)–
Bitfarms Ltd. (“Bitfarms”, or the “Company”) (TSXV:BITF) will release its 2020 third quarter results on Thursday November 26, 2020 prior to market open. The Company’s senior management will be hosting a webcast presentation at 10:00 AM Eastern Time on November 26, 2020 to discuss Bitfarms’ financial and operating results. To view the webcast presentation, please register using the following link:

https://onlinexperiences.com/Launch/QReg/ShowUUID=24FF76E5-C7B6-45CC-B66D-D650BAAE8D3E

The financial results and presentation will also be available on the Company’s website at www.bitfarms.com

About Bitfarms Ltd.

The Company owns and operates computing centres that power the global decentralized financial economy. Bitfarms provides computing power to cryptocurrency networks such as Bitcoin, earning fees from each network for securing and processing transactions. Powered by clean and competitively priced hydroelectricity, Bitfarms operates 5 computing centres in Québec, Canada. Bitfarms’ experienced management team includes industrial-scale data center operators and capital markets professionals, focused on building infrastructure for the future by developing and hosting the ecosystem growing around blockchain-based technologies.

To learn more about Bitfarms’ events, developments and online communities:

https://www.facebook.com/bitfarms/

https://twitter.com/Bitfarms_io

https://www.instagram.com/bitfarms/

https://www.linkedin.com/company/bitfarms/

Website: www.bitfarms.com

Mauro Ferrara

Interim Chief Financial Officer and Corporate Secretary

Bitfarms Ltd.

+1.514.691-6228

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Software Technology Hardware

MEDIA:

Conference

Stifel 2020 Virtual Healthcare Conference

Date

Tuesday, November 17, 2020

Time

9:20 a.m. Eastern time

A live webcast and replay of the presentation can be accessed on the company’s website, www.therapeuticsmd.com, on the Home Page or under the “Investors & Media” section.

About TherapeuticsMD

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and the proceeds that may be generated by such divestiture; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the efficacy supplement for the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.

Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: General Health Women Consumer Health Pharmaceutical

MEDIA:

Logo
Logo
Posted on

Sensyne Health appoints President, North America, to lead US expansion

Sensyne Health appoints President, North America, to

lead US expansion      

Oxford, U.K. 13 November 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that it has appointed Derek Baird to its senior management team as President, North America. Derek will join Sensyne on 01 December 2020 and will focus on driving the commercial development of the Company’s North American operations, building Sensyne’s presence in the US and recruiting a US-based team.

Derek joins Sensyne from AVIA, a digital transformation partner for health systems and payers, where he served as Senior Vice President, Growth. Prior to joining AVIA Derek was a Senior Vice President at healthcare software company Health Language (acquired by Wolters Kluwer Health), and has held senior product and marketing roles at Zynx Health and ambulatory electronic health records provider Practice Partner.

Derek is a US national and will be based in the US.    

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

“I’m delighted that Derek is joining the Sensyne team. His extensive experience, combined with a deep knowledge of US healthcare technology and US health systems, will be invaluable as we further capitalise on what we have already achieved in the UK by driving forward our expansion into the US and building a transatlantic business.” 

Derek Baird, said:

“I’ve been impressed with the progress that Sensyne has already made in the UK in such a short space of time. It is clear the value that Sensyne delivers in the UK is equally applicable to US heathcare systems and life sciences companies. I’m excited to bring the Sensyne vision and unique business model to the US market.”

-ENDS-

For more information please contact:

Sensyne Health (www.sensynehealth.com) +44 (0) 330 058 1845
Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer  
Michael Norris, Interim Chief Financial Officer  
Consilium Strategic Communications +44 (0) 7780 600290
Mary-Jane Elliott  
Sukaina Virji  
Melissa Gardiner  

CSC
[email protected]
 		 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

Posted on

RioCan Real Estate Investment Trust Announces November 2020 Distribution

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — RioCan Real Estate Investment Trust (“RioCan”) (TSX: REI.UN) today announced a distribution of 12 cents per unit for the month of November. The distribution will be payable on December 7, 2020 to unitholders of record as at November 30, 2020.


About RioCan

RioCan is one of Canada’s largest real estate investment trusts. RioCan owns, manages and develops retail-focused, increasingly mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at September 30, 2020, our portfolio is comprised of 221 properties with an aggregate net leasable area of approximately 38.4 million square feet (at RioCan’s interest) including office, residential rental and 16 development properties.

Information contact:
Kim Lee
Vice President, Investor Relations, RioCan REIT
(416) 646-8326
[email protected]

Posted on

Sprott Announces 2020 Third Quarter Results

TORONTO, Nov. 13, 2020 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three months ended September 30, 2020.

As previously disclosed, all financial figures are now reported in US dollars unless indicated otherwise.

Financial Overview (3 months results)

  • Assets Under Management (“AUM”) were $16.3 billion as at September 30, 2020, up $2.4 billion (17%) from June 30, 2020.
  • Total net revenues (net of commission expenses, trailer fees and sub-advisor fees, carried interest and performance fee payouts) were $31.3 million, reflecting an increase of $14.1 million (82%) from the 3 months ended September 30, 2019.
  • Total expenses (excluding commission expenses, trailer fees and sub-advisor fees, carried interest and performance fee payouts) were $21 million, reflecting an increase of $9.6 million (85%) from the 3 months ended September 30, 2019. The increase was primarily due to:
    • Higher salaries from new hires related to the acquisition of the Tocqueville gold strategies (“the Acquisition”) and higher AIP on increased revenues and earnings across the Company.
    • Higher contingent consideration related to the Acquisition as a result of higher estimated future operating performance of the acquired assets
    • These increases were partially offset by lower LTIP amortization and SG&A in the quarter.
  • Net income was $8.7 million ($0.36 per share), reflecting an increase of $4.4 million from the 3 months ended September 30, 2019.
  • Adjusted base EBITDA was $12 million ($0.49 per share), an increase of $4.4 million (58%) from the 3 months ended September 30, 2019.

Subsequent Events

  • On November 12, 2020, the Sprott Board of Directors announced an 8.7% increase to the Company’s quarterly dividend, effective immediately

“Our assets under management have increased by 76% in 2020, driven by strong precious metals prices, significant sales in our exchange listed products segment and excellent performance in our managed equities segment,” said Peter Grosskopf, CEO of Sprott.  “As a result of our robust financial performance and strong capital position, we are pleased to announce that the Board of Directors has approved an increase of the quarterly dividend to USD $0.25 per share, effective immediately. We are confident that our business will support this dividend level without impacting our ability to fund future growth initiatives.”

“During the third quarter, Sprott was also added to the S&P/TSX Composite Index and ranked  among the 30 top-performing TSX stocks over a three-year period based on dividend adjusted share price appreciation, through inclusion in the TSX30 program,” added Mr. Grosskopf.

 

Assets Under Management (3 months results)

(In millions $) AUM
Jun. 30, 2020		 Net
    Inflows (1)		 Market
Value
Changes		 Other (2) AUM
Sep. 30, 2020
Exchange Listed Products            
     – Physical Trusts 9,181 890 1,060 — 11,131  
     – ETFs 328 27 26 — 381  
  9,509 917 1,086 — 11,512  
             
Managed Equities            
     – Precious Metals Strategies 2,279 (57) 225 — 2,447  
     – Other 277 19 16 — 312  
  2,556 (38) 241 — 2,759  
             
Lending 893 17 18 (22) 906 (3)
             
Other 935 — 147 — 1,082  
             
Total 13,893 896 1,492 (22) 16,259  

(1) See ‘Net Inflows’ in the key performance indicators (non-IFRS financial measures) section of this MD&A.

(2) Includes new AUM from fund acquisitions and lost AUM from fund divestitures and capital distributions of our lending LPs.

(3) $1.2 billion of committed capital remains uncalled, of which $0.5 billion earns a commitment fee (AUM), and $0.7 billion does not (future AUM).

Dividends

On November 12, 2020, a dividend of US$0.25 per common share was declared for the quarter ended September 30, 2020.

Conference Call and Webcast

A conference call and webcast will be held today, November 13, 2020 at 10:00 am ET to discuss the Company’s financial results. To participate in the call, please dial (855) 458-4215 ten minutes prior to the scheduled start of the call and provide conference ID 6191323  A taped replay of the conference call will be available until Friday, November 20, 2020 by calling (855) 859-2056, reference number 6191323. The conference call will be webcast live at www.sprott.com and https://edge.media-server.com/mmc/p/6kpdmwn6 

 *Non-IFRS Financial Measures

This press release includes financial terms (including AUM, net revenues, expenses, adjusted base EBITDA and net sales) that the Company utilizes to assess the financial performance of its business that are not measures recognized under International Financial Reporting Standards (“IFRS”). These non-IFRS measures should not be considered alternatives to performance measures determined in accordance with IFRS and may not be comparable to similar measures presented by other issuers. For additional information regarding the Company’s use of non-IFRS measures, including the calculation of these measures, please refer to the “Non-IFRS Financial Measures” section of the Company’s Management’s Discussion and Analysis and its annual financial statements available on the Company’s website at www.sprott.com and on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

A reconciliation from net income to adjusted base EBITDA is shown below:

  3 months ended
(in thousands $) Sept. 30, 2020 Sept. 30, 2019
     
Net income for the periods 8,704   4,336  
Adjustments:    
Interest expense 320   297  
Provision (recovery) for income taxes 1,613   1,473  
Depreciation and amortization 992   893  
EBITDA 11,629   6,999  
     
Other adjustments:    
(Gains) losses on investments (1) (4,408 ) (600 )
Non-cash stock-based compensation 871   1,212  
Other expenses (2) 3,932   1  
Adjusted EBITDA 12,024   7,612  
     
Other adjustments:    
Carried interest and performance fees —   —  
Carried interest and performance fee related expenses —   —  
Adjusted base EBITDA 12,024   7,612  

(1)  This adjustment removes the income effects of certain gains or losses on short-term investments, co-investments and digital gold strategies to ensure the reporting objectives of our EBITDA metric as described above are met.

(2)  In addition to the items outlined in Note 6, Other expenses also includes severance and new hire accruals of $0.2 million for the 3 months ended (3 months ended September 30 – $0.2 million) and excludes income attributable to non-controlling interests (see Other expenses in Note 6 of the interim financial statements)

Forward Looking Statements

Certain statements in this press release contain forward-looking information and forward-looking statements (collectively referred to herein as the “Forward-Looking Statements”) within the meaning of applicable Canadian and U.S. securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify Forward-Looking Statements. In particular, but without limiting the forgoing, this press release contains Forward-Looking Statements pertaining to: (i) market outlook and future metal prices, including that long-term trends that will determine precious metals prices remain in place and that we expect that future monetary and fiscal interventions by central banks are likely to increase in scale and frequency; (ii) activity in new product development and the pursuit of new avenues for growth; and (iii) the declaration, payment and designation of dividends and confidence that our business will support the dividend level without impacting our ability to fund future growth initiatives.

Although the Company believes that the Forward-Looking Statements are reasonable, they are not guarantees of future results, performance or achievements. A number of factors or assumptions have been used to develop the Forward-Looking Statements, including, without limitation: (i) the impact of increasing competition in each business in which the Company operates will not be material; (ii) quality management will be available; (iii) the effects of regulation and tax laws of governmental agencies will be consistent with the current environment; and (iv) the impact of COVID-19; and (v) those assumptions disclosed under the heading “Significant Accounting Judgments, Estimates and Changes in Accounting Policies” in the Company’s MD&A for the period ended June 30, 2020. Actual results, performance or achievements could vary materially from those expressed or implied by the Forward-Looking Statements should assumptions underlying the Forward-Looking Statements prove incorrect or should one or more risks or other factors materialize, including: (i) difficult market conditions; (ii) poor investment performance; (iii) failure to continue to retain and attract quality staff; (iv) employee errors or misconduct resulting in regulatory sanctions or reputational harm; (v) performance fee fluctuations; (vi) a business segment or another counterparty failing to pay its financial obligation; (vii) failure of the Company to meet its demand for cash or fund obligations as they come due; (viii) changes in the investment management industry; (ix) failure to implement effective information security policies, procedures and capabilities; (x) lack of investment opportunities; (xi) risks related to regulatory compliance; (xii) failure to manage risks appropriately; (xiii) failure to deal appropriately with conflicts of interest; (xiv) competitive pressures; (xv) corporate growth which may be difficult to sustain and may place significant demands on existing administrative, operational and financial resources; (xvi) failure to comply with privacy laws; (xvii) failure to successfully implement succession planning; (xviii) foreign exchange risk relating to the relative value of the U.S. dollar; (xix) litigation risk; (xx) failure to develop effective business resiliency plans; (xxi) failure to obtain or maintain sufficient insurance coverage on favourable economic terms; (xxii) historical financial information being not necessarily indicative of future performance; (xxiii) the market price of common shares of the Company may fluctuate widely and rapidly; (xxiv) risks relating to the Company’s investment products; (xxv) risks relating to the Company’s proprietary investments; (xxvi) risks relating to the Company’s lending business; (xxvii) risks relating to the Company’s brokerage business; (xxviii) those risks described under the heading “Risk Factors” in the Company’s annual information form dated February 27, 2020; and (xxix) those risks described under the headings “Managing Risk: Financial” and “Managing Risk: Non-Financial” in the Company’s MD&A for the period ended June 30, 2020. In addition, the payment of dividends is not guaranteed and the amount and timing of any dividends payable by the Company will be at the discretion of the Board of Directors of the Company and will be established on the basis of the Company’s earnings, the satisfaction of solvency tests imposed by applicable corporate law for the declaration and payment of dividends, and other relevant factors. The Forward-Looking Statements speak only as of the date hereof, unless otherwise specifically noted, and the Company does not assume any obligation to publicly update any Forward-Looking Statements, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

About Sprott

Sprott is an alternative asset manager and a global leader in precious metal and real asset investments. Through its subsidiaries in Canada, the US and Asia, Sprott is dedicated to providing investors with specialized investment strategies that include Exchange Listed Products, Managed Equities, Lending and Brokerage. Sprott’s common shares are listed on the New York Stock Exchange under the symbol (NYSE: SII) and Toronto Stock Exchange under the symbol (TSX: SII). For more information, please visit www.sprott.com.

Investor contact information:

Glen Williams
Managing Director
Investor and Institutional Client Relations
(416) 943-4394
[email protected]